– USA, NC – Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage biotechnology company using its ARCUS genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced the appointment of Michael Amoroso to its Board of Directors as President and CEO, effective October 15, 2021, to succeed Co-Founder Matt Kane.
“We are very pleased that Michael will lead the Precision BioSciences team as we embark on the next phase of the company’s growth and seek to maximize the opportunities for our ARCUS platform,” said Board Chair, Kevin Buehler. “Michael’s deep commercial and operational expertise in hematology, oncology, and gene therapy is an excellent fit for Precision and very relevant as we develop our strategy for late-stage clinical development and ultimately aim for commercialization. We believe that Michael’s priorities and motivations align well with the culture at Precision BioSciences and position him to successfully lead the Precision team as we pursue novel treatments to overcome cancer and cure genetic diseases.”
About Michael Amoroso
Mr. Amoroso is a biotech CEO with significant operational experience leading organizations focused on cell and gene therapies. He brings extensive experience leading teams across research, clinical development, regulatory and medical affairs, and commercial operations, with direct operational experience in the U.S. and major world markets with a particular focus on oncology drugs, including CAR T cell therapies for hematologic malignancies.
Mr. Amoroso is currently President and CEO of Abeona Therapeutics, Inc., a fully-integrated gene and cell therapy company. Before this role, Mr. Amoroso served as Abeona’s Chief Commercial Officer and COO, responsible for overseeing the operational management of Abeona, including research and clinical development, regulatory, medical, commercial, corporate affairs, and business development. Previously, Mr. Amoroso was the SVP and Chief Commercial Officer at Kite Pharma, Inc. He held various senior-level executive positions at leading biopharmaceutical companies, including Eisai Inc., Celgene Corporation, and began his biopharmaceutical career at Aventis (now Sanofi S.A.). Mr. Amoroso earned his Executive M.B.A. in Management from the Stern School of Business, New York University, and his B.A. in Biological Sciences, summa cum laude, from Rider University.
“I am excited to join Precision BioSciences as its next President and CEO and to advance Precision’s novel genome editing platform, ARCUS, in two cutting edge sectors of biotech, allogeneic CAR T therapy and in vivo gene editing. I look forward to working alongside co-founders Derek Jantz, CSO and Jeff Smith, CTO, and the team of Precisioneers who are driving the development of our potentially breakthrough treatments with their perseverance and continuous technical innovation. I’m particularly optimistic about the potential opportunity to bring novel cell therapies to patients who suffer from hematologic malignancies, and about the prospects of filing three Investigational New Drug/Clinical Trial applications in the next three years for our gene-editing treatments,” said Mr. Amoroso.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene editing candidates to cure genetic and infectious diseases where no adequate treatments exist.
For more information: https://precisionbiosciences.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
